Treatment of inflamed pterygia or residual pterygial bed

British Journal of Ophthalmology

Volumn 93, Issue 7, 2009, Pages 864-865

  Mansour, A M ^a,b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CASE REPORT; CONJUNCTIVA; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PTERYGIUM; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MICROVESSELS; MIDDLE AGED; PHACOEMULSIFICATION; PTERYGIUM; VITRECTOMY;

EID: 67649666490     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.155291     Document Type: Article

References (22)

1. Paris Fdos S, de Farias CC, Melo GB, et al. Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence. Cornea 2008;27:406-410 (Pubitemid 351591476)
2. Pikkel J, Porges Y, Ophir A. Halting pterygium recurrence by postoperative 5-fluorouracil. Cornea 2001;20:168-171 (Pubitemid 32174086)
3. Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 2006;113:1102-1109 (Pubitemid 43947236)
4. Chang YS, Chen WC, Tseng SH, et al. Subconjunctival mitomycin C before pterygium excision: an ultrastructural study. Cornea 2008;27:471-475 (Pubitemid 351591486)
5. Avisar R, Bar S, Weinberger D. Preoperative injection of mitomycin C in combined pterygium and cataract surgery. Cornea 2005;24:406-409 (Pubitemid 40586627)
6. Donnenfeld ED, Perry HD, Fromer S, et al. Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. Ophthalmology 2003;110:1012-1016 (Pubitemid 36560504)
7. Bau DT, Chiang CC, Tsai YY, et al. Evaluation of transforming growth factor and vascular endothelial growth factor polymorphisms in Taiwan Chinese patients with pterygium. Eur J Ophthalmol 2008;18:21-26
8. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003;22:473-477 (Pubitemid 36759043)
9. Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology 2005;112:1023-1030 (Pubitemid 40797457)
10. Lee DH, Cho HJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001;20:738-742 (Pubitemid 34506473)
11. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 2007;69:925-927 (Pubitemid 47248101)
12. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye 2007;21:1095-1101 (Pubitemid 47263760)
13. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007;2:251-275 (Pubitemid 46448066)
14. Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007;35:745-748 (Pubitemid 350090533)
15. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalm Vis Sci 2007;48:2545-2552 (Pubitemid 351261204)
16. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008;33:23-28 (Pubitemid 351156952)
17. Tsai YY, Chiang CC, Bau DT, et al. Vascular endothelial growth factor gene 460 polymorphism is associated with pterygium formation in female patients. Cornea 2008;27:476-479 (Pubitemid 351591487)
18. Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008;27:357-362
19. Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008;27:349-352
20. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-431
21. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807 (Pubitemid 46846656)
22. Rasier R, Artunay O, Yuzbazioglu E, et al. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye. Published Online First: 12 December 2008.